Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of Waterloo

$25,000.00

Development of bioink formulation for 3D printing of tissue models

EF 2016-17

Résumé
Everyone has needed pharmaceuticals at some point for an illness. Before they were used to treat humans, they were tested on animals. Animal testing is expensive, unethical and inaccurate when it comes to human responses to drugs. Yet, it is the method of choice for drug screening prior to clinical trial. 9215581 Canada Inc. (Ourotech) is aiming to solve this problem by 3D printing human tissues that are more representative of drug effects on humans and do not require animal experimentation. Ourotech is creating a bioink in a syringe that can be attached to any 3D printer/dispensing system to 3D print living human cells. The inks contain everything necessary to protect, print, signal and feed cells, so pharmaceutical companies just need to add the cells, culture after printing, and test their drugs. The proposed project focuses on a main ingredient of the bioink, which is the crosslinkable polymer for making 3D hydrogel scaffolds. This is the first joint effort between Ourotech and the Tang lab at the University of Waterloo. The funding will support the development of chemical approaches to generate novel hyaluronic acid-based polymers, which crosslink in a two-stage process, and thus enable biocompatible printing and hardening of 3D structures. This technology will lead to ink formulations that can potentially be used to create various cancer models, such as lung cancer, ovarian cancer, prostate cancer, and potentially brain cancer.
Programme
Engage Grants Program
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
493539-2015
Name nom
Tang, XiaowuShirley
Department département
Chemistry
Organization id
33
Institution établissement
University of Waterloo
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
2000
Research subject group en
Materials science and technology
Research subject group fr
Science et technologie des matériaux
Research subject en
Materials science and technology
Research subject fr
Science et technologie des matériaux
Partie
1
Nb partie
1
Application title
Development of bioink formulation for 3D printing of tissue models
Keyword
NSERC
Application summary
Everyone has needed pharmaceuticals at some point for an illness. Before they were used to treat humans, they were tested on animals. Animal testing is expensive, unethical and inaccurate when it comes to human responses to drugs. Yet, it is the method of choice for drug screening prior to clinical trial. 9215581 Canada Inc. (Ourotech) is aiming to solve this problem by 3D printing human tissues that are more representative of drug effects on humans and do not require animal experimentation. Ourotech is creating a bioink in a syringe that can be attached to any 3D printer/dispensing system to 3D print living human cells. The inks contain everything necessary to protect, print, signal and feed cells, so pharmaceutical companies just need to add the cells, culture after printing, and test their drugs. The proposed project focuses on a main ingredient of the bioink, which is the crosslinkable polymer for making 3D hydrogel scaffolds. This is the first joint effort between Ourotech and the Tang lab at the University of Waterloo. The funding will support the development of chemical approaches to generate novel hyaluronic acid-based polymers, which crosslink in a two-stage process, and thus enable biocompatible printing and hardening of 3D structures. This technology will lead to ink formulations that can potentially be used to create various cancer models, such as lung cancer, ovarian cancer, prostate cancer, and potentially brain cancer.